Soleno Therapeutics Inc.

Filter

År

Typ

Språk

2023-01-26 14:00:00 Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

2022-12-19 14:00:00 Soleno Therapeutics Announces Financing Commitment for up to $60 Million

2022-11-09 22:05:00 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

2022-10-03 14:00:00 Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

2022-08-10 22:05:00 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

2022-07-11 22:05:00 Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference

2022-06-13 22:05:00 Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS

2022-06-07 14:00:00 Soleno Therapeutics Announces Presentations at ENDO 2022

2022-05-19 22:05:00 Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology

2022-05-10 22:01:00 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

2022-05-02 22:05:00 Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome

2022-04-01 17:49:01 Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering

2022-03-31 22:05:00 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

2022-03-29 14:30:00 Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering

2022-03-28 22:01:00 Soleno Therapeutics Announces Proposed Underwritten Public Offering

2022-03-09 14:00:00 Running for Research – Prader-Willi Syndrome to Fund Multi-Center Study of DCCR in Early Phase Prader-Willi Syndrome

2022-02-08 14:00:00 Soleno Therapeutics to Participate in the BIO CEO & Investor Conference

2022-01-28 22:48:49 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2022-01-24 14:00:00 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

2021-11-19 22:05:00 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2021-09-16 22:05:00 Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

2021-05-21 14:00:00 Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021

2021-05-05 22:01:00 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

2021-04-15 02:40:17 Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall

2021-03-09 22:01:00 Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference

2021-03-03 22:01:00 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

2021-02-05 14:00:00 Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

2021-01-04 14:00:00 Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

2020-12-11 14:30:00 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Språk